Measurement of Urinary Catabolites of PACs as Biomarkers of Consumption of Cranberry Extracts
NCT ID: NCT02087735
Last Updated: 2016-10-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
15 participants
INTERVENTIONAL
2014-01-31
2014-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Cranberry Extract and Urinary Infection Prevention: a Clinical Trial
NCT02572895
Urinary Proanthocyanidin-A2 as a Biomarker of Compliance to Intake of Cranberry Products
NCT01687114
Cranberry on Urinary Tract Infections
NCT01881165
Effects of Cranberry-Containing Products in Women With Recurrent Urinary Tract Infections (UTIs)
NCT00100061
Cranberry and Quillaja on Symptoms of Uncomplicated UTI
NCT04496726
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
BASIC_SCIENCE
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
cranberry extract 1
One capsule with a proanthocyanidin standardized cranberry extract of 36 mg and one capsule of placebo cranberry extract.
Cranberry extract
The aim of this pilot study is to evaluate the urinary catabolites of PACs as a biomarker of consumption of cranberry extracts within 9 hours of intercourse. Once a week, for 3 weeks, the women will receive a sequence of 3 different cranberry extracts (72 mg, 36 mg and 2mg (placebo)). The participant will have to collect its urine for a period of 9 hours in 3 different containers (one different container for 3 hours).
cranberry extract 2.
Two capsules with a proanthocyanidin standardized cranberry extract of 36 mg.
Cranberry extract
The aim of this pilot study is to evaluate the urinary catabolites of PACs as a biomarker of consumption of cranberry extracts within 9 hours of intercourse. Once a week, for 3 weeks, the women will receive a sequence of 3 different cranberry extracts (72 mg, 36 mg and 2mg (placebo)). The participant will have to collect its urine for a period of 9 hours in 3 different containers (one different container for 3 hours).
cranberry extract 3.
Two capsules with a proanthocyanidin standardized cranberry extract of 2 mg.
Cranberry extract
The aim of this pilot study is to evaluate the urinary catabolites of PACs as a biomarker of consumption of cranberry extracts within 9 hours of intercourse. Once a week, for 3 weeks, the women will receive a sequence of 3 different cranberry extracts (72 mg, 36 mg and 2mg (placebo)). The participant will have to collect its urine for a period of 9 hours in 3 different containers (one different container for 3 hours).
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Cranberry extract
The aim of this pilot study is to evaluate the urinary catabolites of PACs as a biomarker of consumption of cranberry extracts within 9 hours of intercourse. Once a week, for 3 weeks, the women will receive a sequence of 3 different cranberry extracts (72 mg, 36 mg and 2mg (placebo)). The participant will have to collect its urine for a period of 9 hours in 3 different containers (one different container for 3 hours).
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* 18 to 40 years.
Exclusion Criteria
* No refrigerator access during the 9 hours of sample collection.
* Women who had or expect to take antibiotic.
* Women who had or expect to take cranberries, blueberries or bilberries in the form of berries, juice or extracts.
* Women who had or expect to take dark chocolate.
* Women who had personal history of acute or chronic renal failure.
18 Years
40 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Laval University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Sylvie Dodin
Sylvie Dodin, MD
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Sylvie Dodin, MD
Role: PRINCIPAL_INVESTIGATOR
Laval University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Laval University, Department of Medecine, Institut sur la nutrition et les aliments fonctionnels (INAF).
Québec, Quebec, Canada
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PACS-2013-SD
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.